MondayJun 27, 2022 2:33 pm

Why More Attention Needs to Be Paid to Paternal Mental Health

We know that pregnancy, giving birth and navigating the first few months as a mother can have an immense toll on women’s mental health. In recent times, there has been an increased push to provide resources for new mothers to help address mental health issues such as postpartum depression. Fathers don’t seem to be getting the same kind of support and resources even though they too experience a multitude of emotions and mental health outcomes after their children are born. Unlike the old days when families had strictly defined gender roles and fathers weren’t as actively involved in their children’s…

Continue Reading

MondayJun 27, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device  Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions…

Continue Reading

MondayJun 27, 2022 2:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that…

Continue Reading

MondayJun 27, 2022 1:30 am

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”).  SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies.  Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered with Silo to study psychedelics’ ability to improve, slow, or even reverse functional decline and memory loss associated with Alzheimer's disease. Associate Professor of Clinical Neurobiology, Dr. Christine Ann Denny, helming the research for Silo,…

Continue Reading

FridayJun 24, 2022 1:59 pm

New Research Says Immune Cell Proliferation May Be Associated with Multiple Sclerosis Onset

New research has discovered that there may be a link between higher levels of immune cells in the blood and multiple sclerosis . For the research, scientists studied the genetic data of a large group of individuals with European ancestry. They found that a specific immune cell known as natural killer cells was associated with a 24% rise in the risk of developing multiple sclerosis. The researchers, whose findings were reported in “Frontiers in Immunology,” state that understanding the link between natural killer cells and multiple sclerosis could help them develop potential therapies for this illness. Multiple sclerosis develops when…

Continue Reading

FridayJun 24, 2022 12:00 pm

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant…

Continue Reading

ThursdayJun 23, 2022 10:02 am

Uncertainty Causes Patients with Systemic Autoimmune Conditions to Be Depressed

Data from new research has revealed a clear link between systemic autoimmune rheumatic disorders and mental health concerns such as anxiety, and depression. These mental health outcomes are due to illness-related uncertainty. Dr. Zachary Wallace from Massachusetts General Hospital states that while current medications have proven to be effective in addressing the symptoms of rheumatoid conditions, patients often struggle to come to terms with their diagnosis and how it will impact the rest of their lives. Katie Willard Virant, a psychotherapist, adds that to live with a chronic illness is to live with a heightened sense of uncertainty. According to…

Continue Reading

WednesdayJun 22, 2022 3:24 pm

Study Suggests Healthcare Workers Don’t Know Enough About Childhood Brain Tumors

A recent survey presented at the recent International Symposium on Pediatric Neuro-Oncology (ISPNO) suggests that healthcare workers have some knowledge gaps when it comes to central nervous system (CNS) tumors in children. For their study, researchers from St. Jude Children’s Research Hospital distributed questionnaires to healthcare providers as part of a cross-sectional survey. Their objective was to evaluate the knowledge these providers had about tumors in children. The questionnaire’s main focus was on the symptoms and imaging indications of central nervous system tumors. Every healthcare provider was invited to fill out the questionnaire before and after an educational seminar, which…

Continue Reading

TuesdayJun 21, 2022 9:58 am

New Study Finds Dose Tapering May Heighten Risk of Opioid Overdoses

New research from the Center for Healthcare Policy and Research at UC Davis has found that dose-reduction programs meant to taper patients off opioids and reduce opioid overdoses can increase the risk of mental health risks and patient overdose in the long term. In the study findings, which were published in “JAMA Network Open,” the researchers noted that patients on higher doses of opioid therapy experienced remarkably higher rates of mental-health crises and overdose in the second year after their doses were tapered down by at least 15%. Opioid tapering is meant to steadily wean patients off opioids over a…

Continue Reading

TuesdayJun 21, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Interview Addresses Company’s Focus on Development of Drug and Device Technologies to Treat Unmet Medical Needs

Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for three of the company’s four products and pending clinical testing Odyssey’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder and patients needing treatment for brain concussion injuries The drug-device combination for treating concussions is advancing in a…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000